These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 39016154)

  • 1. Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD.
    Sabinari I; Horakova O; Cajka T; Kleinova V; Wieckowski MR; Rossmeisl M
    Physiol Res; 2024 Aug; 73(Suppl 1):S295-S320. PubMed ID: 39016154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
    Kelley NS
    Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary omega-3 and omega-6 polyunsaturated fatty acids modulate hepatic pathology.
    Khadge S; Sharp JG; Thiele GM; McGuire TR; Klassen LW; Duryee MJ; Britton HC; Dafferner AJ; Beck J; Black PN; DiRusso CC; Talmadge J
    J Nutr Biochem; 2018 Feb; 52():92-102. PubMed ID: 29175671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intake of a Western diet containing cod instead of pork alters fatty acid composition in tissue phospholipids and attenuates obesity and hepatic lipid accumulation in mice.
    Liisberg U; Fauske KR; Kuda O; Fjære E; Myrmel LS; Norberg N; Frøyland L; Graff IE; Liaset B; Kristiansen K; Kopecky J; Madsen L
    J Nutr Biochem; 2016 Jul; 33():119-27. PubMed ID: 27155918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. n-3 polyunsaturated fatty acids in phospholipid or triacylglycerol form attenuate nonalcoholic fatty liver disease via mediating cannabinoid receptor 1/adiponectin/ceramide pathway.
    Chen YF; Fan ZK; Gao X; Zhou F; Guo XF; Sinclair AJ; Li D
    J Nutr Biochem; 2024 Jan; 123():109484. PubMed ID: 37866428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD.
    Nobili V; Alisi A; Musso G; Scorletti E; Calder PC; Byrne CD
    Crit Rev Clin Lab Sci; 2016; 53(2):106-20. PubMed ID: 26463349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of various ratios of DHA/EPA supplementation on high-fat diet-induced liver damage in mice.
    Shang T; Liu L; Zhou J; Zhang M; Hu Q; Fang M; Wu Y; Yao P; Gong Z
    Lipids Health Dis; 2017 Mar; 16(1):65. PubMed ID: 28356106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action.
    Scorletti E; Byrne CD
    Mol Aspects Med; 2018 Dec; 64():135-146. PubMed ID: 29544992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the Co-Administration of N-3 Fatty Acids and Olive Oil Components in Preclinical Nonalcoholic Fatty Liver Disease Models: A Mechanistic View.
    Valenzuela R; Videla LA
    Nutrients; 2020 Feb; 12(2):. PubMed ID: 32075238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial.
    Nogueira MA; Oliveira CP; Ferreira Alves VA; Stefano JT; Rodrigues LS; Torrinhas RS; Cogliati B; Barbeiro H; Carrilho FJ; Waitzberg DL
    Clin Nutr; 2016 Jun; 35(3):578-86. PubMed ID: 26047766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel fatty acid mimetic with pan-PPAR partial agonist activity inhibits diet-induced obesity and metabolic dysfunction-associated steatotic liver disease.
    Sahin C; Melanson JR; Le Billan F; Magomedova L; Ferreira TAM; Oliveira AS; Pollock-Tahari E; Saikali MF; Cash SB; Woo M; Romeiro LAS; Cummins CL
    Mol Metab; 2024 Jul; 85():101958. PubMed ID: 38763495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high-fat diet: possible role of endocannabinoids.
    Rossmeisl M; Jilkova ZM; Kuda O; Jelenik T; Medrikova D; Stankova B; Kristinsson B; Haraldsson GG; Svensen H; Stoknes I; Sjövall P; Magnusson Y; Balvers MG; Verhoeckx KC; Tvrzicka E; Bryhn M; Kopecky J
    PLoS One; 2012; 7(6):e38834. PubMed ID: 22701720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR-/- mice.
    Depner CM; Traber MG; Bobe G; Kensicki E; Bohren KM; Milne G; Jump DB
    PLoS One; 2013; 8(12):e83756. PubMed ID: 24358308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omega-3 phospholipids from fish suppress hepatic steatosis by integrated inhibition of biosynthetic pathways in dietary obese mice.
    Rossmeisl M; Medrikova D; van Schothorst EM; Pavlisova J; Kuda O; Hensler M; Bardova K; Flachs P; Stankova B; Vecka M; Tvrzicka E; Zak A; Keijer J; Kopecky J
    Biochim Biophys Acta; 2014 Feb; 1841(2):267-78. PubMed ID: 24295779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer.
    Jump DB; Depner CM; Tripathy S; Lytle KA
    Adv Nutr; 2015 Nov; 6(6):694-702. PubMed ID: 26567194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms related to the hepatoprotective effects of antioxidant-rich extra virgin olive oil supplementation in rats subjected to short-term iron administration.
    Barrera C; Valenzuela R; Rincón MÁ; Espinosa A; Echeverria F; Romero N; Gonzalez-Mañan D; Videla LA
    Free Radic Biol Med; 2018 Oct; 126():313-321. PubMed ID: 30153476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease.
    Alwayn IP; Gura K; Nosé V; Zausche B; Javid P; Garza J; Verbesey J; Voss S; Ollero M; Andersson C; Bistrian B; Folkman J; Puder M
    Pediatr Res; 2005 Mar; 57(3):445-52. PubMed ID: 15659701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
    Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
    Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxytyrosol prevents reduction in liver activity of Δ-5 and Δ-6 desaturases, oxidative stress, and depletion in long chain polyunsaturated fatty acid content in different tissues of high-fat diet fed mice.
    Valenzuela R; Echeverria F; Ortiz M; Rincón-Cervera MÁ; Espinosa A; Hernandez-Rodas MC; Illesca P; Valenzuela A; Videla LA
    Lipids Health Dis; 2017 Apr; 16(1):64. PubMed ID: 28395666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of stearidonic acid-enriched soybean oil on fatty acid profile and metabolic parameters in lean and obese Zucker rats.
    Casey JM; Banz WJ; Krul ES; Butteiger DN; Goldstein DA; Davis JE
    Lipids Health Dis; 2013 Oct; 12():147. PubMed ID: 24139088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.